A detailed history of Sargent Bickham Lagudis LLC transactions in Merck & Co., Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 24,824 shares of MRK stock, worth $2.46 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
24,824
Previous 24,645 0.73%
Holding current value
$2.46 Million
Previous $2.12 Million 29.67%
% of portfolio
0.23%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 23, 2023

BUY
$87.44 - $112.11 $15,651 - $20,067
179 Added 0.73%
24,824 $0
Q3 2022

Oct 27, 2022

SELL
$84.53 - $94.96 $49,957 - $56,121
-591 Reduced 2.34%
24,645 $2.12 Million
Q2 2022

Jul 13, 2022

BUY
$83.49 - $94.64 $43,331 - $49,118
519 Added 2.1%
25,236 $2.3 Million
Q1 2022

Apr 27, 2022

SELL
$73.51 - $82.4 $35,725 - $40,046
-486 Reduced 1.93%
24,717 $2.03 Million
Q4 2021

Jan 18, 2022

SELL
$72.28 - $90.54 $6,143 - $7,695
-85 Reduced 0.34%
25,203 $1.93 Million
Q3 2021

Nov 05, 2021

SELL
$71.68 - $78.83 $10,321 - $11,351
-144 Reduced 0.57%
25,288 $1.9 Million
Q2 2021

Jul 19, 2021

BUY
$70.31 - $77.77 $17,507 - $19,364
249 Added 0.99%
25,432 $1.98 Million
Q1 2021

May 24, 2021

BUY
$68.86 - $81.11 $118,714 - $139,833
1,724 Added 7.35%
25,183 $1.94 Million
Q4 2020

May 24, 2021

SELL
$71.77 - $79.65 $123,731 - $137,316
-1,724 Reduced 6.85%
23,459 $1.92 Million
Q4 2020

May 24, 2021

BUY
$71.77 - $79.65 $114,832 - $127,440
1,600 Added 6.78%
25,183 $1.94 Million
Q3 2020

Sep 01, 2021

BUY
$73.18 - $82.95 $88,694 - $100,535
1,212 Added 5.42%
23,583 $1.96 Million
Q2 2020

Sep 07, 2021

BUY
$70.42 - $80.13 $4,013 - $4,567
57 Added 0.26%
22,371 $1.73 Million
Q1 2020

Sep 07, 2021

BUY
$63.36 - $87.82 $31,236 - $43,295
493 Added 2.26%
22,314 $1.72 Million
Q4 2019

Sep 14, 2021

BUY
$77.58 - $87.54 $16,291 - $18,383
210 Added 0.97%
21,821 $1.99 Million
Q3 2019

Sep 14, 2021

BUY
$76.08 - $82.93 $5,021 - $5,473
66 Added 0.31%
21,611 $1.82 Million
Q2 2019

Sep 13, 2021

BUY
$69.84 - $81.59 $768 - $897
11 Added 0.05%
21,545 $1.81 Million
Q1 2019

Sep 13, 2021

SELL
$69.58 - $79.36 $12,941 - $14,760
-186 Reduced 0.86%
21,534 $1.79 Million
Q4 2018

Sep 13, 2021

BUY
$65.24 - $75.71 $33,729 - $39,142
517 Added 2.44%
21,720 $1.66 Million
Q3 2018

Sep 13, 2021

BUY
$57.69 - $67.84 $576 - $678
10 Added 0.05%
21,203 $1.5 Million
Q2 2018

Sep 13, 2021

BUY
$50.83 - $59.72 $609 - $716
12 Added 0.06%
21,193 $1.29 Million
Q1 2018

Sep 13, 2021

SELL
$50.96 - $59.23 $28,639 - $33,287
-562 Reduced 2.58%
21,181 $1.15 Million
Q4 2017

Sep 13, 2021

SELL
$51.62 - $61.64 $74,126 - $88,515
-1,436 Reduced 6.2%
21,743 $1.22 Million
Q3 2017

Sep 13, 2021

BUY
$58.67 - $63.13 $35,202 - $37,878
600 Added 2.66%
23,179 $1.48 Million
Q2 2017

Sep 13, 2021

SELL
N/A
-701 Reduced 3.01%
22,579 $1.45 Million
Q1 2017

Sep 13, 2021

SELL
N/A
-1,004 Reduced 4.13%
23,280 $1.48 Million
Q4 2016

Sep 13, 2021

BUY
N/A
327 Added 1.36%
24,284 $1.43 Million
Q3 2016

Sep 13, 2021

BUY
N/A
1,265 Added 5.57%
23,957 $1.5 Million
Q2 2016

Sep 07, 2021

BUY
N/A
124 Added 0.55%
22,692 $1.31 Million
Q1 2016

Sep 07, 2021

BUY
N/A
22,568
22,568 $1.19 Million

Others Institutions Holding MRK

About Merck & Co., Inc.


  • Ticker MRK
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,533,280,000
  • Market Cap $251B
  • Description
  • Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...
More about MRK
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.